Keeley Teton Advisors LLC Sells 1,780 Shares of Pfizer Inc. (NYSE:PFE)

Keeley Teton Advisors LLC lowered its position in Pfizer Inc. (NYSE:PFE) by 8.5% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 19,253 shares of the biopharmaceutical company’s stock after selling 1,780 shares during the quarter. Keeley Teton Advisors LLC’s holdings in Pfizer were worth $534,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in PFE. Gamco Investors INC. ET AL raised its stake in Pfizer by 123.9% in the first quarter. Gamco Investors INC. ET AL now owns 533,251 shares of the biopharmaceutical company’s stock worth $14,798,000 after buying an additional 295,139 shares in the last quarter. Stonebridge Capital Advisors LLC increased its stake in shares of Pfizer by 35.2% during the first quarter. Stonebridge Capital Advisors LLC now owns 26,586 shares of the biopharmaceutical company’s stock valued at $738,000 after purchasing an additional 6,921 shares in the last quarter. Toronto Dominion Bank increased its stake in shares of Pfizer by 4.8% during the first quarter. Toronto Dominion Bank now owns 3,649,335 shares of the biopharmaceutical company’s stock valued at $101,269,000 after purchasing an additional 165,719 shares in the last quarter. Sheaff Brock Investment Advisors LLC increased its stake in shares of Pfizer by 1.5% during the first quarter. Sheaff Brock Investment Advisors LLC now owns 77,938 shares of the biopharmaceutical company’s stock valued at $2,163,000 after purchasing an additional 1,188 shares in the last quarter. Finally, Heron Bay Capital Management increased its stake in shares of Pfizer by 513.2% during the first quarter. Heron Bay Capital Management now owns 135,857 shares of the biopharmaceutical company’s stock valued at $3,770,000 after purchasing an additional 113,700 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Price Performance

NYSE PFE traded up $1.00 on Friday, reaching $30.77. The company had a trading volume of 35,657,080 shares, compared to its average volume of 30,301,530. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.78 and a current ratio of 1.05. The firm’s 50 day moving average price is $28.54 and its 200 day moving average price is $27.76. Pfizer Inc. has a 12 month low of $25.20 and a 12 month high of $37.19.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.56 by $0.26. The company had revenue of $14.88 billion for the quarter, compared to the consensus estimate of $13.87 billion. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. Pfizer’s revenue for the quarter was down 19.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.23 EPS. Equities research analysts predict that Pfizer Inc. will post 2.38 EPS for the current year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 3rd. Shareholders of record on Friday, July 26th will be issued a $0.42 dividend. The ex-dividend date is Friday, July 26th. This represents a $1.68 dividend on an annualized basis and a yield of 5.46%. Pfizer’s dividend payout ratio is currently -2,799.53%.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on PFE. Morgan Stanley raised their target price on shares of Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a research note on Thursday, May 2nd. BMO Capital Markets reaffirmed an “outperform” rating and set a $36.00 target price (up previously from $33.00) on shares of Pfizer in a research note on Thursday, May 2nd. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research note on Wednesday, July 10th. Finally, Barclays raised their target price on shares of Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 10th. Nine investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $34.50.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.